Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and Wegovy, as well as their competing therapies for type 2 diabetes, Mounjaro and Ozempic.But dominance in a pharmaceutical segment never lasts forever. Over a long-enough period, new entrants can copy the winners' products and produce generic versions for a fraction of the cost. Therefore, ongoing innovation is the only sustainable way forward.Now, as the two companies position themselves to win the future of those markets by developing next-gen therapies, they're both heading in the same direction in their pipeline strategies and spending huge sums of money along the way. And if their competitive matchup today is any indication, there's a significant chance they could both be winners in an emerging new battleground, powering tremendous gains for shareholders.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool